Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
"Right-to-try" legislation aimed at giving severely ill patients access to drug treatments not yet approved by US FDA failed to win support from the needed super-majority in a Tuesday night vote in the US House. Before the vote, the bill's scope was narrowed by removing medical device provisions, and making it applicable only to those facing death within a matter of months. A Senate version still in play retains the device language.
Latest From United States, Policy & Regulation
The US Centers for Medicare and Medicaid Services March 16 said it will cover next-generation sequencing diagnostic laboratory tests for advanced cancers, broadening its final determination to cover use in relapsed, refractory and stage III cancers, while dropping "coverage with evidence development" conditions.
US FDA is working with manufacturers, researchers and other stakeholders to assemble a comprehensive network of registries of cardiac device data. But cardiologists and device firms say the project faces multiple challenges.
In another blow from the US government, securities regulators have severely penalized Theranos and its cofounder, Elizabeth Holmes, for allegedly lying to investors to raise funds.
The head of US FDA's device center, Jeff Shuren, wants three manufacturers of duodenoscopes to fulfill their obligation to conduct post-market surveillance studies. Check out what he said about Olympus, Fujifilm and Pentax Medical here.
While lab-developed test (LDTs) remain under a US FDA enforcement discretion policy, the agency is working on several fronts to offer appealing regulatory pathways for advanced diagnostic services, FDA Commissioner Scott Gottlieb told American Clinical Laboratory Association members.
The US Federal Trade Commission hosted a sometimes-contentious discussion on proposed changes to its Contact Lens Rule on March 8. One issue up for debate was which methods are appropriate when a contact-lens seller needs to confirm a prescription with a patient's eye doctor.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.